Detection of residual pertussis toxin in vaccines using a modified ribosylation assay

Vaccine

Volumn 21, Issue 1-2, 2002, Pages 44-52

  Yuen, Chun Ting ^a   Canthaboo, Catpagavalli ^a   Menzies, J Alan ^b   Cyr, Terry ^b   Whitehouse, Larry W ^b   Jones, Chris ^a   Corbel, Michael J ^a   Xing, Dorothy ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals   (Canada)

Author keywords

HPLC; Pertussis; Ribosylation

Indexed keywords

ALUMINUM SALT; FLUORESCEIN; HISTAMINE; PEPTIDE DERIVATIVE; PERTUSSIS TOXIN; ACELLULAR VACCINE; FLUORESCENT DYE; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; PERTUSSIS VACCINE;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHO CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG QUALITY; ENZYMATIC ASSAY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; SENSITIZATION; TOXICITY; ANIMAL; BIOASSAY; CHEMISTRY; HAMSTER; METHODOLOGY; SENSITIVITY AND SPECIFICITY; STANDARD;

ANIMALS; BIOLOGICAL ASSAY; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; FLUORESCENT DYES; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HETEROTRIMERIC GTP-BINDING PROTEINS; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SENSITIVITY AND SPECIFICITY; VACCINES, ACELLULAR;

EID: 0037159618     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00446-2     Document Type: Article

References (31)

1. Fine P., Clarkson J. Reflections on the efficacy of pertussis vaccines. Rev. Infect. Dis. 9:1987;866-883.
2. Centres for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children-recommendations of the advisory committee on immunization practices (ACIP). Morbid Mortal Weekly Rep 1997;46(RR-7):1-25.
3. Greco D, Salmaso S, Mastrantonio P, Progetto Pertosase Working Group. A controlled trail of two acellular vaccines and one whole cell vaccine against pertussis. New Engl J Med 1996;334:341-8.
4. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two component acellular, a five component acellular, and a whole cell pertussis vaccine. New Engl J Med. 334:1996;349-355.
5. Munoz J. Biological activities of pertussigen. In: Sekura R, Moss J, Vaughan M, editors. Pertussis toxin. New York: Academic Press, 1985. p. 1-18.
6. Donnelly S., Loscher C., Lynch M., Mills K. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1β in a new murine model for analysis of neuronal side effects of vaccination. Infect. Immun. 69:2001;4217-4223.
7. Sato Y., Arai H., Suzuki K. Leukocytosis-promoting factor of Bordetella pertussis. III. Its identity with protective antigen. Infect. Immun. 9:1974;801-810.
8. Xing D., Canthaboo C., Corbel M. Effect of pertussis toxin on induction of nitric oxide in murine macrophages and protection in vivo. Vaccine. 18:2000;2110-2119.
9. Guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines. In: WHO Technical Series, Forty-Seventh Report, 1998. p. 57-76.
10. Pertussis vaccine (acellular, component, adsorbed). In: European Pharmacopoeia, 2000. p. 1050-2.
11. Kappelle I., Gun W., Marsman F., Hendriksen C., Donk H. Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine. Biologicals. 25:1997;41-57.
12. Gillenius P., Jaatmaa E., Askelof P., Granstrom M., Tiru M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J. Biological Standardization. 13:1985;61-66.
13. Tamura M., Nogimori K., Murai S., Yajima M., Ito X., Katada T.et al. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry. 21:1982;5516-5522.
14. Sekura R., Fish F., Manclark C., Made B., Zhang Y. Pertussis toxin: affinity purification of a new ADP-ribosyltransferase. J. Biol. Chem. 258:1983;14647-14651.
15. Katada T., Ui M. Islet-activating protein: a modifier of receptor-mediated regulation of rat islet adenylate cyclase. J. Biol. Chem. 256:1981;8310-8317.
16. Milligan G. Techniques used in the identification and analysis of function of pertussis toxin-sensitive guanine nucleotide binding proteins. Biochem. J. 255:1988;1-13.
17. Katada T., Ui M. Directmodification of the membrance adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc. Natl. Acad. Sci. U.S.A. 79:1982;3129-3133.
18. Katada T., Ui M. ADP-ribosylation of the specific membrane protein of C6 cells by islet-activating protein associated with modification of adenylate cyclase activity. J. Biol. Chem. 257:1982;7210-7216.
19. Graf R., Codina J., Birnbaumer L. Peptide inhibitors of ADP-ribosylation by pertussis toxin are substrates with affinities comparable to those of the trimeric GTP-binding protein. Mol. Pharmacol. 42:1992;760-764.
20. +. Biochemistry. 36:1997;8215-8223.
21. i3C20 by the S1 subunit and deletion peptides of S1 of pertussis toxin. Biochemistry. 34:1995;1070-1075.
22. Cyr T, Menzies J, Calver J, Whitehouse L. A quantitative analysis for the ADP-ribosylation activity of pertussis toxin: an enzymatic-HPLC coupled assay applicable to formulated whole cell and acellular pertussis vaccine products. Biologicals 2001;29:81-95.
23. Kreeftenberg J. Collaborative study on the candidate reference materials JNIH-3, JNIH-4 and JNIH-5 for the assay of acellular pertussis vaccines. In: WHO report BS/88.1586, 1988.
24. Pizza M., Covacci A., Bartoloni A., Perugini M., Nencioni L., Magistris M.et al. Mutants of pertussis toxin suitable for vaccine development. Science. 246:1989;497-499.
25. Rappuoli R. Rational design of vaccines. Nat. Med. 3:1997;374-376.
26. Seagroatt V., Sbeffield F. A collaborative assay of the proposed second international standard for pertussis vaccine and of the proposed first British Standard for pertussis vaccine. J. Biological Standardization. 9:1981;351-365.
27. Redhead K., Das R. A collaborative assay of the proposed Third British Reference Preparation for pertussis vaccine and of the relative potencies of the second international standard and the Second British Reference Preparation for Pertussis Vaccine. Biologicals. 19:1991;107-111.
28. Tamura M., Nogimori K., Yajima M., Ase K., Ui M. A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. J. Biol. Chem. 258:1983;6756-6761.
29. Ui M, Pertussis toxin as a valuable probe for G-protein involvement in signal transduction. In: Moss J, Vaughan M, editors. ADP-ribosylating toxins and G-protein. Washington, DC, American Society for Microbiology, 1990. p. 45-77.
30. Burns D., Kenimer J., Manclark C. Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. Infect. Immun. 55:1987;24-28.
31. Ibsen P. The effect of formaldehyde hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine. 14:1996;359-368.